Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Lifecore Biomedical Inc.

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Lifecore Biomedical today. The company’s shares opened today at $6.94. According to Tip...

Current Quarter	$-0.15	Next Quarter	$-0.2
Current Year	$NA	Next Year	$-0.82
QoQ Growth	-33.3%	YoY Growth	NaN%
3Y EPS CAGR	+0.0%	Target Price	$10.00
Consensus	Buy	Upside	+30.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LFCR	$7.64	+3.66%	276.55K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LFCR	$7.64	+3.7%	276.55K
3
4
5
6

LFCR

LFCR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Lifecore Biomedical Inc. Data in Excel

Get Lifecore Biomedical Inc. Data in Excel